Primary Care ERectile Function Outcome Registry for Men
PERFORM
1 other identifier
observational
255
0 countries
N/A
Brief Summary
The PERFORM registry is a structured, real-world data platform designed to systematically capture patient characteristics, disease severity and treatment patterns of Erectile Dysfunction (ED) across Pakistan. By reflecting routine clinical practice, an ED registry provides valuable insights into the disease epidemiology, unmet needs, and variations in care across populations. It supports evidence-based decision-making, helps identifying early predictors, and inform guideline development, health policy, and personalized management strategies in male sexual health.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Feb 2026
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 8, 2026
CompletedFirst Posted
Study publicly available on registry
January 21, 2026
CompletedStudy Start
First participant enrolled
February 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 5, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 31, 2027
January 21, 2026
January 1, 2026
12 months
January 8, 2026
January 14, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Descriptive data of frequency, severity of ED in Pakistan
Prevalence
Baseline
Descriptive data [age, income (derivative of socio-economic class), rural/urban population and occupation]
Demographics
baseline
Secondary Outcomes (2)
Age of diabetes in ED patients
baseline
Duration of ED
baseline
Eligibility Criteria
Adult Male ED patients
You may qualify if:
- Adult male above 18 years of age
- Married
- Diabetic
- Patient reports erectile dysfunction (symptomatic).
- Patient is eligible to be prescribed sildenafil by treating clinician.
You may not qualify if:
- If at any other PDE-5 inhibitor (sildenafil, tadalafil, vardenafil, avanafil)
- Concurrent use of organic nitrates (any form: glyceryl trinitrate, isosorbide mononitrate/dinitrate) - absolute contraindication
- Recent or unstable cardiovascular disease
- Myocardial infarction or stroke in last 3 months
- Unstable angina
- Uncontrolled arrhythmia or heart failure NYHA III-IV
- Resting hypotension (SBP \< 90 mmHg) or uncontrolled hypertension (SBP \> 180 mmHg) per treating clinician
- Known severe hepatic impairment or severe renal impairment on dialysis (if local clinician deems unsafe)
- Known hypersensitivity to sildenafil or excipients
- Concomitant use of potent CYP3A4 inhibitors (e.g., ritonavir) - unless clinician documents safe plan/dose adjustment
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- CROSS SECTIONAL
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 8, 2026
First Posted
January 21, 2026
Study Start
February 6, 2026
Primary Completion (Estimated)
February 5, 2027
Study Completion (Estimated)
May 31, 2027
Last Updated
January 21, 2026
Record last verified: 2026-01